Amgen Inc. lost requests for several judgments in Lindis Biotech GmbH’s patent-infringement lawsuit seeking damages for sales of the leukemia treatment Blincyto, according to a federal judge’s mixed ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...